UNSPSC 51383201: Clidanac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H19ClO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UA6HM01WAK, chemically known as 6-chloro-5-cyclohexyl-2,3-dihydro-1h-indene-1-carboxylic acid but generally known as clidanac, which bears US NIH Compound Identifier 120108. European Medicines Agency schedules Clidanac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06659MIG.

UNSPSC 51383201 Clidanac is a Commodity code that covers naloxone and drug deactivation systems purchased by state and local health authorities to support overdose-response and substance-abuse prevention initiatives. The scope of work encompasses the procurement of finished naloxone units and Safe Drug Deactivation Systems for annual deployment, typically in quantities ranging from hundreds to thousands of units depending on jurisdiction need. Issuing bodies under this code include county health departments and community health agencies; the recent activity reflects procurement by county-level public-health functions rather than school districts, transit authorities, or other state or local entity types.

Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The solicitation required electronic bid submission through the county's e-Procurement Portal, with a response deadline of July 26, 2023, at 2:00 pm, and included standard compliance requirements (drug-free workplace certification, E-Verify authorization, workers' compensation and general-liability insurance). The contract carried a two-year initial term with an optional one-year renewal and featured potential FEMA funding with associated federal compliance obligations. Geographic activity under the code is currently limited to Florida based on available recent opportunities; no additional states or jurisdictions show naloxone-procurement solicitations in the dataset.